1YBottom 25% of the group
Rank 50 of 63 funds
Return +15.53%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 50No. 1 is SCBGENOME(E) +62.13%
SCB Healthcare Innovation
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
SCBIHEALT(SSFE) invests through the master fund BNP Paribas Funds Health Care Innovators 98.77%
This fundSCBIHEALT(SSFE)
The fund that actually investsBNP Paribas Funds Health Care InnovatorsThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.59%
Merck & MRK6.49%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per BNP Paribas fact sheet
Over the past year it was in the bottom 25% of its group; over 3 years it returned +7.97% per year (Below half the group)
No. 1 is SCBGENOME(E) +62.13%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | MAX |
|---|---|---|---|---|---|---|---|---|
| +11.47% | +2.56% | +6.82% | +8.66% | +11.98% | +22.08% | +15.62% | +25.88% | −2.83% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar |
|---|
Largest drawdown in the selected period −42.76% Previous peak 16 Aug 2022 (NAV 6.3569) → Trough 8 Aug 2025 (NAV 3.6388) · Not back to the previous peak as of 2 Nov 2026
Currently −21.69% from the peak NAV of 6.3569 (16 Aug 2022)
Over 3 years, SCBIHEALT(SSFE) returned 0.44 per unit of volatility, ranking 26 of 37 funds · The highest is TBIOTECH (0.88)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) ได้แก่ กองทุน BNP Paribas Funds Health Care Innovators - Class I Capitalisation (กองทุนหลัก) ในสกุลเงินยูโร (EUR) กองทุนหลักบริหารโดย BNP PARIBAS ASSET MANAGEMENT Luxembourg จดทะเบียนภายใต้กฎหมายของประเทศลักเซมเบ… Its largest holdings are หน่วยลงทุน BNP HEALTH CARE INNOV-I 99.40% (fact sheet 31 Aug 2026)
Risk level 7 of 8 (High risk). Since 10 Jun 2022, its NAV has fallen as much as −42.76% from its peak.
Actual total expense ratio (TER) 0.11% a year, against a ceiling of 1.83%. Management fee 0.00%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 31 Jul 2026)
It has a dividend policy but has not paid any dividends yet
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 31 Jul 2026, 82.39% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · SCBIHEALT(SSFE): pays dividends, TER 0.11% · SCBIHEALTH(A): no dividends, TER 1.71% · SCBIHEALTH(D): see the conditions in the prospectus · SCBIHEALTH(E): no dividends, TER 0.11% · SCBIHEALTH(IN): see the conditions in the prospectus · SCBIHEALTH(P): see the conditions in the prospectus · SCBIHEALTH(R): see the conditions in the prospectus · SCBIHEALTH(SSF): pays dividends, TER 1.71%
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
ABBVIE ABBV
AstraZeneca AZN.L5.99%
Gilead Sciences GILD5.08%
Vertex Pharmaceuticals VRTX4.83%
Intuitive Surgical ISRG4.32%
Thermo Fisher TMO4.12%
Jazz Pharmaceuticals JAZZ3.40%
argenx ARGX3.12%Eli Lilly and Co LLYDiabetes and weight-loss drugs
Merck & MRKHospitals, medicines and medical equipment
ABBVIE ABBVHospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Gilead Sciences GILDA US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
Intuitive Surgical ISRGHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Jazz Pharmaceuticals JAZZHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Based on the master fund's share of this fund's value (98.77% as of 31 Jul 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from BNP Paribas · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +21.97% per year
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −3.3 | +0.8 | −3.7 | −2.8 | +2.9 | +7.4 | −1.4 | +4.9 | −0.4 | +8.3 | −1.0 | · | +11.5* |
| 2025 | +5.7 | +0.4 | −8.4 | −5.8 | −4.1 | −1.2 | +1.3 | +2.4 | +1.6 | +9.8 | +7.8 | −3.8 | +4.2 |
| 2024 | −3.4 | +2.0 | +3.1 | −6.7 | −1.2 | +3.0 | −0.0 | +2.1 | −1.6 | −2.6 | +5.0 | −5.3 | −5.9 |
| 2023 | +3.2 | −6.0 | +0.3 | +1.3 | −2.1 | +0.2 | +3.6 | −10.7 | −9.9 | −12.7 | +7.6 | +10.3 | −16.5 |
| 2022 | · | · | · | · | · | +1.1 | +7.7 | +1.9 | −6.8 | +2.1 | +2.4 | −1.5 | +6.4* |